Abstract
Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Current Pharmaceutical Design
Title:Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Volume: 24 Issue: 1
Author(s): Adriana Trompetero, Aldemar Gordillo, Mora Carolina del Pilar, Velasquillo María Cristina and Rosa Helena Bustos Cruz*
Affiliation:
- Universidad de la Sabana, Faculty of Medicine, Therapeutic Evidence Group, Chía,Colombia
Keywords: Alzheimer’s disease (AD), astrocyte, Blood-brain barrier (BBB), glial cell, Parkinson’s disease (PD), nanotechnology, drug delivery, nanoparticle (NP), liposome, dendrimer, quantum dot, nanocarrier, nanoliposome, nanomicelle.
Abstract: Neurodegenerative disorders (NDDs) are characterized by the progressive loss of structure or neuron function, often associated with neuronal death. Treatments for neurodegenerative diseases only address symptoms without having any disease-modifying effect but serious side effects. Currently, there is no effective treatment for NDDs. This is due to the poor flow of drugs to the blood-barrier brain (BBB) which does not allow macromolecules like proteins and peptides to pass through it. Targeted drug delivery to the central nervous system (CNS) for the diagnosis and treatment of NDDs, such as Alzheimer’s disease (AD), is restricted due to the limitations posed by the BBB as well as opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Nanotechnology thereby presents a broad approach for transporting molecules through the BBB, thus allowing the entry of substances acting directly on the site affected by the disease. The aim of this review is to outline current strategies in nanotechnology for treating Alzheimer’s and Parkinson’s diseases.
Export Options
About this article
Cite this article as:
Trompetero Adriana , Gordillo Aldemar, del Pilar Carolina Mora , Cristina María Velasquillo and Bustos Cruz Helena Rosa*, Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach, Current Pharmaceutical Design 2018; 24 (1) . https://dx.doi.org/10.2174/1381612823666170828133059
DOI https://dx.doi.org/10.2174/1381612823666170828133059 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Anionic Peptide Fragments in 1N4R Human Tau Protein Aggregation
Protein & Peptide Letters Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry The Click Test: A Novel Tool to Quantify the Age-Related Decline of Fast Motor Sequencing of the Thumb
Current Aging Science The Role of Glucose in the Pathogenesis of Alzheimers Disease Revisited:What Does it Tell us About the Therapeutic use of Lithium?
Central Nervous System Agents in Medicinal Chemistry Dendrimers and the Double Helix - From DNA Binding Towards Gene Therapy
Current Topics in Medicinal Chemistry Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities
Current Neuropharmacology Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Ether Glycerophospholipids and Their Potential as Therapeutic Agents
Current Organic Chemistry Ongoing Electroencephalographic Activity Associated with Cortical Arousal in Transgenic PDAPP Mice (hAPP V717F)
Current Alzheimer Research Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Effects of the Novel Non-Peptidyl Low Molecular Weight Radical Scavenger IAC in Different Models of Inflammation: A New Perspective in Anti-Inflammatory Therapy
Current Medicinal Chemistry Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Metal-Score as a Potential Non-Invasive Diagnostic Test for Alzheimer’s Disease
Current Alzheimer Research Brain Structural Effects of Psychopharmacological Treatment in Bipolar Disorder
Current Neuropharmacology